8-K: Delcath Systems Secures Permanent J-Code for HEPZATO, Boosting Reimbursement Prospects

Delcath Systems has obtained a permanent J-code for its HEPZATO treatment from the Centers for Medicare & Medicaid Services, effective April 1, 2024, which is expected to streamline billing and improve patient access.

Summary

• Delcath Systems has announced that the Centers for Medicare & Medicaid Services (CMS) has established a permanent, product-specific J-code (J9248) for its HEPZATO treatment.
• The J-code, which will be effective on April 1, 2024, is a Healthcare Common Procedure Coding System Level II identifier used by payors to streamline the billing of Medicare Part B drugs.
• CMS has recognized that the melphalan hydrochloride in the HEPZATO KIT is not substitutable with existing melphalan hydrochloride due to its different dosage and delivery method.
• HEPZATO KIT is approved for liver-directed treatment of adult patients with metastatic uveal melanoma (mUM) with specific conditions related to liver involvement and extrahepatic disease.
• The company believes that the J-code will facilitate patient access to this important treatment and enable accurate and efficient reimbursement.

Sentiment

Score: 8

Explanation: The document is positive due to the establishment of a permanent J-code, which is a significant step towards commercial success for HEPZATO. However, there are still risks and uncertainties associated with commercialization and market adoption.

Positives

• The establishment of a permanent J-code is expected to facilitate patient access to HEPZATO.
• The J-code will streamline the reimbursement process for the HEPZATO KIT.
• CMS has acknowledged the unique nature of the melphalan hydrochloride in the HEPZATO KIT.
• The J-code is a significant step towards accurate and efficient reimbursement of the HEPZATO KIT.

Risks

• The company's commercialization plans for HEPZATO could face uncertainties.
• There are risks associated with managing the HEPZATO KIT supply chain, including securing critical components.
• Successful FDA inspections of the company's and its suppliers' facilities are necessary.
• The company must successfully implement and manage the HEPZATO KIT Risk Evaluation and Mitigation Strategy.
• There are uncertainties regarding the potential benefits of HEPZATO as a treatment.
• The company's ability to obtain reimbursement for HEPZATO is not guaranteed.
• The company's ability to enter into necessary purchase and sale agreements with users of HEPZATO is not guaranteed.

Future Outlook

The company anticipates that the permanent J-code will facilitate patient access to HEPZATO and streamline the reimbursement process, but there are risks and uncertainties associated with commercialization, supply chain management, regulatory approvals, and market adoption.

Management Comments

• Gerard Michel, Delcath's Chief Executive Officer, stated that the establishment of the permanent J-code for HEPZATO will facilitate patient access to this important treatment.
• Gerard Michel also noted that this is a significant step towards accurate and efficient reimbursement of the HEPZATO KIT, facilitating access for patients.

Industry Context

This announcement is significant for the interventional oncology space, as it addresses a key hurdle in the adoption of new treatments: reimbursement. The J-code will likely make HEPZATO more accessible to patients and could set a precedent for other novel therapies.

Comparison to Industry Standards

• The establishment of a product-specific J-code is a positive development for Delcath, as it simplifies the reimbursement process, which is often a barrier for new medical treatments.
• Other companies in the oncology space, such as Exact Sciences with their Cologuard test, have also benefited from specific J-codes, which have helped drive adoption and market penetration.
• The HEPZATO KIT's unique delivery system and high-dose chemotherapy approach differentiate it from standard intravenous melphalan treatments, justifying the need for a specific J-code.
• The approval of the J-code is a positive signal for the potential of liver-directed therapies in the treatment of metastatic uveal melanoma, a difficult-to-treat cancer.

Stakeholder Impact

• Shareholders are likely to view this news positively as it improves the commercial prospects of HEPZATO.
• Patients with metastatic uveal melanoma will benefit from improved access to this treatment.
• Payors will have a streamlined billing process for HEPZATO.
• The company's employees may see increased job security and growth opportunities.

Next Steps

• The company will focus on the commercialization of HEPZATO.
• The company will manage the HEPZATO KIT supply chain.
• The company will ensure successful FDA inspections of its facilities and those of its third-party suppliers/manufacturers.
• The company will implement and manage the HEPZATO KIT Risk Evaluation and Mitigation Strategy.
• The company will work to obtain reimbursement for the HEPZATO KIT.
• The company will enter into necessary purchase and sale agreements with users of the HEPZATO KIT.

Key Dates

Keywords

HEPZATO, J-code, melphalan, Delcath Systems, CMS, reimbursement, metastatic uveal melanoma, liver cancer, interventional oncology, Medicare